Íslenska
Search
My pages
Main menu
Close
  • Medicinal products
  • Development
  • Medical Devices
  • Regulated entities
  • Pricing and Reimbursement
  • Published Material
  • IMA
  • Medicinal products
    • About Medicinal products
    • Importation by Individuals of Medicinal Products for Personal Use
    • Marketing Authorisations
      • Conditions for Marketing
      • Electronic Applications
      • Package labelling and leaflets
      • Other Registrations/Authorisations
      • RMS Requests
      • Text Processing
      • Withdrawals
      • Zero Day Procedure
    • Pharmacovigilance
      • Report an Adverse Drug Reaction
    • Quality Standards
    • Reported Medicine Shortage – Overview
    • Safety Features of Medicinal Products
  • Development
    • About Development
    • Clinical Trials
      • Application for a Clinical Trial
      • Clinical Trials Information System (CTIS)
      • Substantial Amendments
      • Notifications and Reports
      • SUSAR Reporting
      • Approvals for Clinical Trial Applications
      • CTFG / VHP
    • Scientific Advice
  • Medical Devices
    • About Medical Devices
    • Instructions for use
    • Use and vigilance of Medical Devices
    • Registration of distributors
    • CE Marking
    • Incident Report for Medical Devices
  • Regulated entities
    • About Regulated entities
    • Manufacturers
    • Medical Centers
    • Narcotic Drugs and Other Controlled Substances
      • Controlled Substances
      • Narcotics
    • Other Regulated Entities
    • Pharmacies
      • Pharmacy License
    • Wholesalers and Distributors
      • Licenses for Import and Wholesale Distribution of Medicinal Products
  • Pricing and Reimbursement
    • About Pricing and reimbursement
    • Icelandic Medicine Price Catalogue
    • The Exchange Rate of the Icelandic Price Catalogue
  • Published Material
    • About Published Material
    • Annual Reports
    • FAQ
    • Forms
    • Guidelines
    • Lists
    • News
  • IMA
    • About IMA
    • Roles and Organization
    • Strategy
    • Employees
    • Fees
    • Laws and Regulations

Type your search and press enter

Type what you want to find

Greinasafn

December 17, 2021

08. What is the meaning of the red warning triangle?

December 17, 2021

07. How long is there an obligation to create and submit PSURs or RMPs after a marketing authorisation was withdrawn?

December 17, 2021

06. How long is there an obligation to continue collection and submission of spontaneous ADR reports after a marketing authorisation of the suspect product was withdrawn?

December 17, 2021

05. Are Marketing Authorisation Holders required to have a Local Contact Person for Pharmacovigilance in Iceland?

December 17, 2021

04. Are Marketing Authorisation Holders required to have a Qualified Person for PharmacoVigilance (QPPV) residing in Iceland?

December 17, 2021

03. Does IMA require literature reports for Icelandic cases? Should a copy of the literature article be attached?

December 17, 2021

02. Is there a list of local literature that the Marketing Authorisation Holders should monitor?

December 17, 2021

01. What happens to ICSRs received by IMA from healthcare professionals and the public?

Want to get the latest news from us?
 

Nánar um persónuverndarstefnu okkar.

  • Facebook
  • Instagram
  • Soundcloud
  • Youtube
  • Contact us
  • Eyðublöð
  • Lög og reglugerðir
  • Lagalegur fyrirvari
  • Fyrir fjölmiðla
  • Persónuverndar­stefna
Lyfjastofnun Gæði - Traust - Þjónusta Vínlandsleið 14 113 Reykjavík S: +354 520-2100
Opening hours Open every weekday in between 9:00 - 15:00 Opnunartímar þjónustuvers Open every weekday in between 9:00 - 15:00
Lyfjastofnun fékk Jafnlaunavottun fyrir árið 2019-2022